Sign in
CompletedNo phase

Pretreatment With CPA-EE, Metformin and Myoinositol in PCOS With High AMH

Key facts

Who runs it
Mst.Sumyara Khatun
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
68 people enrolled
Started
12 Aug 2024
Ended
20 Feb 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cyproterone Acetate, Ethinyl Estradiol Drug Combination
  • Metformin 500 mg
  • Myoinositol 750mg
Record updated
7 April 2026

Who can take part

Age
18 years to 35 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • PCOS
  • 18-35 years
  • Body Mass Index (BMI): 18.5-29.9 kg/m²
  • Infertility
  • Serum AMH level ≥ 5ng/ml

Who cannot take part

  • Women having metformin or other drug that could influence hormone metabolism at least 3 months before the study
  • Endocrine disorder (Hyperprolactinaemia,Uncontrolled hypothyroidism , Diabetes mellitus (DM) type 2,congenital adrenal hyperplasia,cushing syndrome)
  • Any known case of pulmonary,cardiac,hepatic \& renal disease
  • Any contraindications to metformin, myoinositol, letrozole \& CPA-EE ie. obesity, thromboembolism, breast carcinoma etc \& hypersensitivity to these drugs
  • Serum AMH level > 10 ng/ml
  • Women with infertility other than anovulation due to PCOS(bilateral tubal block,uterine factor,endometriosis)
  • Abnormal semen parameter

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Women with PCOS with high AMH randomly allocated into group A \& B.Cyproterone acetate plus ethinyl estradiol,metformin \& myoinositol in group A and Cyproterone acetate plus ethinyl estradiol \& metformin are given in group B.Then letrozole 5 mg day 2 to day 6 is given \& ovarian response is seen in day 12 for 3 subsequent 3 months .

The 2 groups in the trial

  • Experimental armCyproterone acetate 2 mg plus ethinyl estradiol 35 mcg once daily ,metformin 500 mTreatment being tested

    Cyproterone acetate 2 mg plus ethinyl estradiol 35 mcg once daily ,metformin 500 mg 3 times daily \& Myoinositol 750 mg 3 times daily for 3 months.After 3 months of pretreatment letrozole 5 mg daily for 5 days from day 2 to day 6 of menstrual cycle is given Ovarian response is seen by day 12 folliculometry observing developing follicle ,mature follicle and endometrial thickness and day 21 serum progesterone.

    Treatment: Cyproterone Acetate, Ethinyl Estradiol Drug Combination, Metformin 500 mg, and Myoinositol 750mg

  • Comparator armCyproterone acetate 2 mg plus ethinyl estradiol 35 mcg once daily ,metformin 500 mgExisting treatment, for comparison

    Cyproterone acetate 2 mg plus ethinyl estradiol 35 mcg once daily ,metformin 500 mg 3 times daily for 3 months.After 3 months of pretreatment letrozole 5 mg daily for 5 days from day 2 to day 6 of menstrual cycle is given Ovarian response is seen by day 12 folliculometry observing developing follicle ,mature follicle and endometrial thickness and day 21 serum progesterone.

    Treatment: Cyproterone Acetate, Ethinyl Estradiol Drug Combination and Metformin 500 mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 April 2026